Thiapride in the treatment of generalized anxiety disorder comorbid with alcoholism

Abstract

Investigation was carried out of the efficacy of Thiapride in the treatment of generalized anxiety disorder (GAD) comorbid with alcohol dependence (F10.2). The main group comprised 32 patients with GAD comorbid with alcohol dependence who received Thiapride therapy at a dose of 400–800mg/day for two weeks. The comparison group consisted of 30 patients with GAD comorbid with alcohol dependence who received alprazolam therapy at a daily dose of 1–3 mg. It was found that Thiapride compared favourably in effectiveness with alprazolam in terms of its reduction of generalized anxiety disorder. The study involved the use of GAD-7 questionnaire. Statistical data processing was conducted using Biostat 4.03 package, differences were considered significant at significance value of p<0.05. Comparison of qualitative signs in unrelated groups was done with use of z-criterion. Results of therapy were assessed within 14 days after starting the medicines. No statistically significant differences were observed in the efficacy of medications (p>0.05) in the investigated groups as measured by the GAD-7. In the patient group that received alprazolam at a dose of 1–3 mg/day there was a reduction in GAD-7 score in 38.1% of cases. In the group of patients receiving Thiapride at a dose of 400–800mg per day a reduction in GAD-7 score occurred in 37.8%.